

SDPL links JV with Cluegenix

*Introduces AI Enabled Smart Lab



(L-R) Dr Somnath Chatterjee, Director, Suraksha Diagnostic Pvt Ltd, Arpan Malhotra, Senior Vice President, Siemens Healthineers, Dr Joydeep Mukherjee, Scientist, University of California, San Francisco, Dr Anne Beyou Zulianiis, Ph.D., Global Scientific Manager, Molecular Diagnostics Product Line, Siemens Healthineers, Dr Daryl Hee, Senior Product Specialist for LC-MS/MS at Shimadzu (Asia Pacific) Pvt Ltd, Singapore and Dr Joe Daniel, Expert in Next generation sequencing and its applications, Thermo Fisher Scientific (Asia Pacific & Japan) during the announcement of the JV between Suraksha Diagnostic Pvt Ltd and Clugenix, a San Francisco based biotech company--EOI Photo

EOI CORRESPONDENT

KOLKATA, FEB 16--/ Suraksha Diagnostic Pvt. Ltd (SDPL), a centre of innovation, is known for pioneering the introduction of latest technologies as well as leading the academic challenge by setting up the only R&D facilities for Clinical work in the field of Genomics. Serving for almost three decades through its 41 centres all over the country is now proud to possess almost every possible diagnostic technology. The only Patho-

logical Lab in Eastern India to have a NGS, LC-MS/MS, FISH, ICP capabilities, with more than 4000 tests enlisted in the scope.

Suraksha now partners with Clugenix a San Francisco based biotech company, led by Dr Joydeep Mukherjee (a globally recognized, multiple award-winning researcher in oncology and infectious diseases genomics in Toronto and UCSF) focused on making translational genomics technologies accessible globally to the Indian population.

Clugenix will make available to Suraksha the latest developments in Molecular Biology. More importantly together they will work to set up the protocols for the Indian population in genomics. A lot of this research being done in house, will help to reduce the cost of these expensive tests considerably. Together we will be launching to design the Next Gen Sequencing panel for Breast Cancer for Indian women as our first Research Project out of this JV. This initiative once again confirms Suraksha's commitment to accelerate the deployment of highly innovative as well as affordable molecular diagnostic solutions to India's patient population.

With the vision of becoming the first-choice diagnostic among people in Eastern India for both routine and specialized tests, Suraksha has not only focused on best technology but simultaneously on affordability. The biggest challenge of ours today is Cancer. The only way to fight this will be through Molecular Biology. The science of Genomics will provide us with the only solutions. To make a significant contribution to this, we have made this JV with Clugenix to devise Indian protocols for these malignancies. A significant sum of Rs 4 crores have been assigned by the BOD for the first year of R&D on this, sources said.